Yunjiang Liu

Pyrotinib or Lapatinib Combined With Capecitabine in HER2–Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study

Fei Ma, Quchang Ouyang, Wěi Li et al. · Journal of Clinical Oncology · 2019 · 335 citations

Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial

Binghe Xu, Qingyuan Zhang, Pin Zhang et al. · Nature Medicine · 2021 · 152 citations · Full text

Breast Oncology, Medicine, Pharmacology +7

Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial

Junjie Li, Ke‐Da Yu, Da Pang et al. · Journal of Clinical Oncology · 2020 · 103 citations · Full text

RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with HER2-positive and HER2-low expressing advanced or metastatic breast cancer: A pooled analysis of two studies.

Jiayu Wang, Yunjiang Liu, Qingyuan Zhang et al. · Journal of Clinical Oncology · 2021 · 102 citations

Breast Oncology, Immunology, Immunotherapeutics +18

Association of p53 expression with poor prognosis in patients with triple-negative breast invasive ductal carcinoma

Jing-ping Li, Xiang-mei Zhang, Zhenzhen Zhang et al. · Medicine · 2019 · 77 citations · Full text

Tumor Biology, Breast Oncology, Medicine +13